Clinigen Group Plc (CLIGF) Downgraded by Zacks Investment Research
Zacks Investment Research downgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a buy rating to a hold rating in a research report sent to investors on Friday morning.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Clinigen Group Plc (NASDAQ CLIGF) opened at 13.90 on Friday. The firm has a market capitalization of $1.60 billion and a PE ratio of 86.34. Clinigen Group Plc has a 52 week low of $8.70 and a 52 week high of $13.90.
COPYRIGHT VIOLATION WARNING: “Clinigen Group Plc (CLIGF) Downgraded by Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/10/clinigen-group-plc-cligf-downgraded-by-zacks-investment-research.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.